Trevena (TRVN) 400+% Upside Potential

Content contained on or made available through this website is for information only. Content does not constitute investment advice. Your use of the information on the website or materials linked from the Web is at your own risk

model23.com intends to enter a long position of Trevena Inc (TRVN), at a break above $2.52 Trevena will soon be submitting a New Drug Application to the FDA, for their drug OLINVO

http://www.trevena.com/about.php

Our lead product candidate is OLINVO™ (oliceridine injection), an innovative new chemical entity that has recently completed Phase 3 pivotal efficacy studies for the management of moderate-to-severe acute pain. OLINVO is designated a Breakthrough Therapy by the U.S. Food and Drug Administration. We also have discovered several other product candidates with the potential to address problems across a wide range of therapeutic areas, including moderate-to-severe acute and chronic pain, and migraine. In addition, we have an early-stage portfolio of drug discovery programs currently in lead optimization.

http://www.trevena.com/OLINVO-how-it-works.php

Trevena (TRVN) Investor Presentation – Slideshow
https://seekingalpha.com/article/4089440-trevena-trvn-investor-presentation-slideshow

Buying Trevena Inc. Could Be A Huge Upside Trade
https://seekingalpha.com/article/4056801-buying-trevena-inc-huge-upside-trade

Analysts price targets average around $10

Short interest is high, which could lead to a nice pop soon, followed by a more sustained uptrend